Efficacy of Everolimus-containing Chemotherapy in HER2- mBC Patients With PI3K/AKT/mTOR Mutations Study

Clinical trial NCT05054166 · COMPLETED

Trial details

NCT number: NCT05054166
Sponsor: Zhejiang Cancer Hospital
Status: COMPLETED
Study type: OBSERVATIONAL

Breast Cancer PI3K/AKT/mTOR Pathway Mutation Everolimus

Start date: 2021-05-01
Primary completion: 2021-08-01
Enrollment: 14

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.